Description
SGN-75 is a humanized anti-CD70 monoclonal antibody attached to a potent, synthetic drug payload, monomethyl auristatin F (MMAF) utilizing Seattle Genetics' proprietary antibody-drug conjugate (ADC) technology. CD70 is expressed on a variety of solid tumors, including renal cell carcinoma, pancreatic, ovarian and lung cancer, as well as multiple myeloma and several types of non-Hodgkin lymphoma. CD70 has limited expression on normal tissue making it an ideal candidate for ADC therapy.

Status
We initiated a phase I clinical trial of SGN-75 in November 2009 to evaluate its safety, tolerability, pharmacokinetic profile and antitumor activity. The trial is enrolling patients with relapsed or refractory non-Hodgkin lymphoma or metastatic renal cell carcinoma. In preclinical studies, SGN-75 demonstrated potent antitumor activity in models of CD70-positive renal cell carcinoma and hematologic malignancies.